Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com -- Cognition Therapeutics Inc (NASDAQ:CGTX) stock surged 27% after the FDA confirmed that the company’s proposed Phase 3 program design for its Alzheimer’s disease drug candidate could support a New Drug Application (NDA).
The clinical-stage neurodegenerative disease drug developer received final minutes from its end-of-Phase 2 meeting with the FDA, which took place on July 9. The agency endorsed Cognition’s plan to enroll adults with mild-to-moderate Alzheimer’s disease who have lower levels of p-tau217 at screening for its Phase 3 trials of zervimesine (CT1812).
According to the company, previous clinical experience has demonstrated that zervimesine can arrest cognitive deterioration by 95% compared to placebo in this specific patient population. This supports using plasma p-tau217 as a predictive biomarker to identify patients most likely to benefit from treatment.
"In the meeting minutes, FDA concurred with our plan to enrich the Phase 3 study population with Alzheimer’s patients who have lower p-tau217," said Anthony Caggiano, MD, PhD, Cognition’s CMO and head of R&D. "Because p-tau217 can be measured by a simple blood test, we expect this strategy will ease the burden on patients. This enrichment strategy may increase the power of the study and reduce trial costs."
The Phase 3 program will randomize participants to either 100mg of oral zervimesine or placebo daily for six months. A key development from the FDA meeting was the agency’s view that two six-month Phase 3 studies could support an NDA filing, potentially accelerating the regulatory timeline for zervimesine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.